2020 vs. EUR 115m in H1 2019) as Eurofins acquired only seven companies in H1 2020, most of them in Q1 as part of discussions initiated prior to the pandemic spreading to Europe and North America. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. Although Eurofins exposure to clinical testing and IVD products is recent (it only started in 2014) and small (under 20% of Group revenues in 2019), cooperation with other Group companies enabled an outsized impact on overall Group results in Q3. Q1 2020 Results May 12, 2020. The extraction kits work with a large range of existing automation equipment for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis using approved IVD kits, thereby enabling laboratories to meet unprecedented demand for COVID testing capacity. ... deliver excellent results, ... We are proud to be named one of the top 700 Diversity Leaders 2020 of 10 000 public and private European companies analysed by the Financial Times. Free Cash Flow to the Firm - Net cash provided by operating activities, less Net capex. Beyond 2022, Eurofins sees a strong outlook for its core Biopharma, Food, Genetic, Cosmetic, Environment and advanced esoteric Clinical testing activities. Results are provided via email within 24 hours of sample receipt. Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information such as “Adjusted Results2 and Separately Disclosed Items3”) that exclude certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Search |  Investor Relations The test can be used to evaluate the efficacy and safety of surgical masks and hygienic masks against COVID-19. Eurofins also expects to bring its leverage (net debt / adjusted EBITDA) below 2x by the end of 2022. Disposals correspond to the sale by Eurofins of business assets to a third party. In August 2020, Eurofins became the … Eurofins Scientific SE … Western Europe remains the largest region for Eurofins, representing c.49% of total Group revenues in Q1 2019, with France generating 20% of total Group revenues, ahead of Germany which accounted for 10% of total Group revenues, whilst Benelux, the UK & Ireland, and the Nordic countries each contributed ca.6% to Q1 2019 revenues. A The 2020 FCFF objective of EUR 500m was introduced in March 2020, but adjusted to EUR 600m in H1 2020 to include the IFRS 16 related reclassification. Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020. The gap to 5% organic growth in Q3 2020 of Eurofins core business is mostly due to some businesses where revenues are still down compared to Q3 2019 due to disturbances caused by the pandemic. Eurofins also launched highly specific serology testing kits to be used by state or private laboratories on most open ELISA systems and expects to reach a production capacity of over 10 million tests per month by end May 2020. Eurofins will hold a conference call with analysts and investors today at 15:00 pm CET to discuss the results and the performance of Eurofins, as well as its outlook, and will be followed by a questions and answers (Q&A) session. In August 2020, Eurofins became the market leader in non-invasive prenatal testing (NIPT) in Japan with the acquisition of GeneTech Inc., a leading player in genetic analysis in Japan with over EUR 10 million revenues in 2019. Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended. 01 March 2021 (TBC) FY 2020 Results Publication: 22 April 2021 (TBC) 2021 Annual General Meeting Eurofins Textile Testing Spain is currently the only laboratory in Europe and one of only three laboratories in the world to offer such a test, which is mandatory for all masks sold in the North American market. This corresponds to the 2019 pro-forma scope. A 2020-2021 FCFF objectives have been restated to take into account the cash flow statement reclassification performed in H1 2020. Organic growth calculated from 23 January in both quarters is 35% 5 Strong demand… Immunology: 57% growth at CER year on year In August 2020, Eurofins Discovery expanded its chemistry capacity to serve customer demand in the growing market of outsourced drug discovery with a new building nearing completion at Eurofins Discovery’s flagship chemistry site at Eurofins Villapharma in Murcia, Spain. Management believes that providing these APMs (Alternative Performance Measures) enhances investors' understanding of the company’s core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts and to the performance of our competitors. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Q4 / FY 2019 Preliminary Results PRESENTATION Preliminary Q4 & FY 2019 Results Feb 10, 2020… Today the Group also announces its new objectives for 2022, in which hopefully the pandemic will have been brought under control and there may be no COVID-19 related impact (neither positive nor negative). catering and hospitality), particularly in France. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff. • Q1 2020 revenues increased 7% year-on-year to EUR 1,142m • 4.1% organic growth ( 4.6% excluding Boston Heart Diagnostics & two laboratories closed due to a fire), showing the resilience of Eurofins underlying markets 2 Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are For 2022, achieve EUR 5.7bn revenues, including a 5% organic CAGR on the core non COVID-19 testing and reagents business from 2019 and EUR 100m from acquisitions (EUR 200m annual revenues consolidated at mid-year), EUR 1.35bn adjusted EBITDA and EUR 800m Free Cash Flow to the Firm. This innovation should go a long way towards making sensitive PCR testing available more broadly by alleviating sampling personnel bottlenecks. Eurofins has received an additional ca. In September 2020, Eurofins Technologies announced that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of aflatoxin M1, I’screen AFLA M1 milk, has been granted AOAC Research Institute Performance Tested Methods. These objectives reflect the continuation of a strong focus on margins and cash flow generation, which has not been derailed by the COVID-19 related activities as these are at or above Group margin and as Eurofins’ 5 years programme to build a world-class fully digitalised hub and spoke laboratory network will be completed soon. Q1 2020 Results May 12, 2020. EBITDA – Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions. For more information, please visit www.eurofins.com or contact: Indeed the pandemic may well have a positive impact on the growth of Eurofins markets over the medium-term. For fiscal 2020, the drug manufacturer lifted its 2020 GAAP EPS outlook, while reaffirmed the non-GAAP EPS target. Beyond this, Eurofins plans to keep a conservative balance sheet, its long-term oriented funding strategy and to retain its Investment Grade credit rating as well as above industry average ESG ratings. Our financial performance is concrete evidence of our positioning in attractive end markets as well as the results of years of investments to build a global network of state-of-the art laboratories and leading R&D teams which has enabled us to mobilise quickly and develop solutions to support healthcare authorities and our clients fighting the pandemic. Over the first nine months of 2020 (NM 2020), revenues grew 12.0% to EUR 3,736m vs. EUR 3,335m during the same period last year. In October 2020, following the recommendations from French health authorities to help combat the second wave of the COVID-19 pandemic, and in order to respond to increased testing demand, Eurofins Biomnis announced it was creating additional capacity of 15,000 tests per day carried out within 24 hours. Careers |  Fastly released their Q1 2020 earnings report on May 6. 2020 Half Year Results 06 August 2020 Eurofins reports solid growth of revenues, profits and cash flows in H1 2020 and continued positive organic growth in Q2 in spite of the COVID-19 pandemic. LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Comments from the CEO, Dr. Gilles Martin: “Q3 2020 was a positive quarter for Eurofins as the Group companies’ agility and speed of innovation enabled it to deliver very strong organic growth in spite of the pandemic. In October 2020, Eurofins U.S. Clinical Diagnostics announced the launch of its Eurofins At-Home COVID-19 Nasal PCR Test. •Q1 2020 revenues increased 7% year-on-year to EUR 1,142m • 4.1% organic growth (4.6% excluding Boston Heart Diagnostics & two laboratories closed due to a fire), showing the resilience of Eurofins underlying markets • Negative impact recorded in Q1 2020 from lockdown measures (China, Europe, USA) not yet compensated by additional COVID-19 testing and research activities U.S. +1 8335 268 347 By geography, Eurofins’ organic growth for Q1 2020 was 2.0% in Europe, 7.1% in North America and 4.6% in the Rest of the World, reflecting the different timings of … More information can be found in the “COVID-19 related business developments” section of this release and at: Given the impossibility to predict the evolution of the COVID-19 pandemic in 2020 and 2021, the Group has decided to leave its objectives for those two years unchanged (2020-2021 objectives were set before the onset of the COVID-19 pandemic). A couple of recent highlights include: Last week, a Eurofins company received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for their At Home COVID-19 Nasal PCR Test. In September 2020, Eurofins Diatherix continued to leverage its extensive respiratory and infectious disease expertise with the launch of Flu Plus, a new test to identify SARS-CoV-2 and five additional and most prevalent viruses associated with respiratory illnesses. This report may not be reproduced ... and Eurofins Lancaster Laboratories Following the recent successful refinancing of the Schuldschein loans maturing in July 2022, Eurofins has extended the average life of its senior debt instruments from 3.3 years to 4.1 years. Some of the many developments that have taken place since the Group reported its H1 2020 results are highlighted below. https://www.eurofins.com/covid-19-response/. Agenda –Q3/NM 2020 Results Presentation. October and November 2020 trading performance has been strong. Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020 – April 28, 2020. Eurofins Scientific SE Eurofins continues to demonstrate its strong commitment towards supporting healthcare providers and national and state authorities in their ongoing efforts to mitigate the spread and impact of the virus.